RSPI (RespireRx Pharmaceuticals) Cyclically Adjusted Book per Share: $-22.92 (As of Sep. 2023)


RSPI RespireRx Pharmaceuticals Inc RSPI
12 GF Score
Price $0.00
View Full Analysis

What is RespireRx Pharmaceuticals Cyclically Adjusted Book per Share?

RespireRx Pharmaceuticals RSPI 12 Cyclically Adjusted Book per Share is $-22.92 as of Sep. 2023. GuruFocus rates RSPI with a GF Score™ of 12/100.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

RespireRx Pharmaceuticals's adjusted book value per share for the three months ended in Sep. 2023 was $-0.044. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $-22.92 for the trailing ten years ended in Sep. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-11), RespireRx Pharmaceuticals's current stock price is $0.0018. RespireRx Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2023 was $-22.92. RespireRx Pharmaceuticals's Cyclically Adjusted PB Ratio of today is .


RespireRx Pharmaceuticals  (OTCPK:RSPI) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


RespireRx Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


RespireRx Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for RespireRx Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RespireRx Pharmaceuticals Cyclically Adjusted Book per Share Chart

RespireRx Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.09 -10.12 -28.23 -31.88 -30.70

RespireRx Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -32.90 -30.70 -28.41 -25.75 -22.92

RSPI vs CNBX, NAVB, IPIX: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, RespireRx Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RespireRx Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RespireRx Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where RespireRx Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


RSPI
12GF Score
RespireRx Pharmaceuticals Inc RSPI
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RespireRx Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, RespireRx Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Sep. 2023 was:

Adj_Book= Book Value per Share /CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-0.044/307.7890*307.7890
=-0.044

Current CPI (Sep. 2023) = 307.7890.

RespireRx Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201312 -95.682 233.049 -126.368
201403 -52.113 236.293 -67.881
201406 -50.935 238.343 -65.776
201409 -47.785 238.031 -61.789
201412 -43.577 234.812 -57.120
201503 -45.270 236.119 -59.011
201506 -22.945 238.638 -29.594
201509 -16.184 237.945 -20.934
201512 -20.808 236.525 -27.077
201603 -26.569 238.132 -34.341
201606 -18.401 241.018 -23.499
201609 -24.099 241.428 -30.723
201612 -25.651 241.432 -32.701
201703 -25.908 243.801 -32.708
201706 -27.646 244.955 -34.738
201709 -26.208 246.819 -32.682
201712 -14.257 246.524 -17.800
201803 -16.022 249.554 -19.761
201806 -15.197 251.989 -18.562
201809 -14.989 252.439 -18.276
201812 -14.871 251.233 -18.219
201903 -16.150 254.202 -19.554
201906 -17.155 256.143 -20.614
201909 -18.198 256.759 -21.815
201912 -17.864 256.974 -21.396
202003 -2.218 258.115 -2.645
202006 -0.354 257.797 -0.423
202009 -0.127 260.280 -0.150
202012 -0.113 260.474 -0.134
202103 -0.095 264.877 -0.110
202106 -0.098 271.696 -0.111
202109 -0.105 274.310 -0.118
202112 -0.102 278.802 -0.113
202203 -0.111 287.504 -0.119
202206 -0.095 296.311 -0.099
202209 -0.097 296.808 -0.101
202212 -0.095 296.797 -0.099
202303 -0.085 301.836 -0.087
202306 -0.058 305.109 -0.059
202309 -0.044 307.789 -0.044

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $-22.92 mean?
RespireRx Pharmaceuticals (RSPI) has a Cyclically Adjusted Book per Share of $-22.92 as of Sep. 2023. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on RespireRx Pharmaceuticals and its competitors.
Is RespireRx Pharmaceuticals' Cyclically Adjusted Book per Share too high?
RespireRx Pharmaceuticals' current Cyclically Adjusted Book per Share is $-22.92. Overall, RespireRx Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does RespireRx Pharmaceuticals' Cyclically Adjusted Book per Share compare to CNBX and NAVB?
RespireRx Pharmaceuticals' Cyclically Adjusted Book per Share of $-22.92 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on RespireRx Pharmaceuticals and its competitors. RespireRx Pharmaceuticals's current Cyclically Adjusted Book per Share is $-22.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RespireRx Pharmaceuticals stock overvalued right now?
RespireRx Pharmaceuticals (RSPI) has a current Cyclically Adjusted Book per Share of $-22.92. The current Cyclically Adjusted Book per Share is $-22.92. RespireRx Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For RespireRx Pharmaceuticals (RSPI), the current Cyclically Adjusted Book per Share is $-22.92 as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

RespireRx Pharmaceuticals Business Description

Address 126 Valley Road, Suite C, Glen Rock, NJ, USA, 07452
RespireRx Pharmaceuticals Inc is engaged in the discovery, value-added development, and commercialization through partners of pharmaceuticals for the treatment of neurological and psychiatric disorders. The pipeline products of the company are dronabinol which is in a 505(b)(2) development ideas for the treatment of OSA (Obstructive Sleep Apnea), a form of sleep apnea; AMPAkines CX1739 for the treatment of bladder control and other conditions associated with spinal injury; CX717 for ADHD and CX1942 which is an injectable dosage formulation and GABAkines lead KRM-II-81 in preclinical development for treatment resistant epilepsy and non-opioid pain management.
12GF Score

Get the complete analysis for RSPI

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price